| 2016-10-18 05:16:45|
SHPG 05:16 10/18 10/18/16
Shire granted EU Marketing Authorization of Onivyde in combination with 5-FU, LV
Shire announced that the European Commission has granted Marketing Authorization of Onivyde, also known as nal-IRI or MM-398, for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil, or 5-FU, and leucovorin, or LV, in adult patients who have progressed following gemcitabine-based therapy. ONIVYDE is the first and only approved treatment option for this patient population.